Amgen said Wednesday that it's too early to know what the impact of job cuts will be on its Boulder and Longmont facilities, which it said employ a combined 1,250 workers.

A 12 percent to 14 percent corporatewide reduction would translate into 150 to 175 job cuts at the Colorado facilities, which conduct research and development, and make medicines for chemotherapy side effects, anemia and osteoarthritis.

The Longmont facility is also where Amgen makes Epogen, an anemia drug whose sales are expected to be hit by a stronger FDA warning label and new Medicare rules restricting reimbursement. Most production of the anemia drug Aranesp, which has been experiencing declining sales, already has been moved from Longmont to Puerto Rico.

At the least, a new facility planned to be built by 2008 at the Longmont campus is on hold.

Amgen spokeswoman Debbi Ford said the company is trying to minimize the impact at all of its sites through attrition, a job freeze and a newly announced voluntary severance program.

Amgen conveyed that message Wednesday to John Cody, president of the Longmont Area Economic Council, and to Susan Graf, president of the Boulder Chamber of Commerce.

"As far as I know, there's nothing to cause them to treat us any differently" than other locations, Cody said. "I think people are in a wait-and-see mode."

The Longmont campus has about 800 employees, according to Amgen. Cody said it also has contractors that push the number close to 1,000.

Last summer, Amgen said it planned to relocate some information systems, human resources and finance employees from its West Coast headquarters to Longmont. About two dozen information systems employees moved to Colorado last year, but none of the other relocations occurred.